Stockscreener 앱 받기
4.23
7.91%
0.31
시간 외 거래:
4.26
0.03
+0.71%
Galectin Therapeutics Inc 주식(GALT)의 최신 뉴스
GALT stock surges 22% — on track for best day in over a year after FDA clears path for late-stage belapectin trial - MSN
Form 4 Galectin Therapeutics Inc For: 25 June By Investing.com - Investing.com Canada
Galectin Therapeutics CMO Jamil Khurram sells $23,728 in shares By Investing.com - Investing.com Canada
Galectin (NASDAQ: GALT) CMO exercises options and sells 7,557 shares under 10b5-1 plan - Stock Titan
Galectin De-Risks Belapectin Path With FDA AlignmentSets Stage For Phase 3 Upside - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Galectin Therapeutics (GALT) and Gilead Sciences (GILD) - The Globe and Mail
GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH - Yahoo Finance
Form 144 GALECTIN THERAPEUTICS INC For: 23 June By Investing.com - Investing.com Australia
Form 144 GALECTIN THERAPEUTICS INC For: 23 June - Investing.com UK
GALT affiliate notifies sale of 8,125 shares (NASDAQ: GALT) - Stock Titan
Galectin Therapeutics (GALT) Announces FDA Agreement for Phase 3 Program - GuruFocus
GALT Stock Surges 22% — On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial - Asianet Newsable
Galectin Therapeutics stock surges on FDA trial agreement - Investing.com
Galectin Therapeutics clears FDA Type C milestone, shares react on NASDAQ - Ad-hoc-news.de
GALT Reiterated by HC Wainwright & Co. -- Price Target Maintained at $11 - GuruFocus
Galectin Therapeutics (GALT) Receives FDA Feedback for Phase 3 T - GuruFocus
Galectin Therapeutics Shares Surge on Positive FDA Meeting, Phase 3 Trial Plans - marketscreener.com
Galectin Therapeutics (GALT) Receives FDA Feedback for Phase 3 Trial Preparation - GuruFocus
Galectin reaches FDA agreement on Phase 3 trial for belapectin - Investing.com
Galecti, FDA agree on Phase 3 trial for MASH drug (GALT:NASDAQ) - Seeking Alpha
Galectin Therapeutics Secures FDA Agreement for Phase 3 Belapectin Trial in MASH Cirrhosis and Portal Hypertension 1 – Minichart - Minichart
Galectin Advances Belapectin to Phase 3 After FDA Alignment - TipRanks
Galectin Therapeutics Reaches FDA Agreement on Phase 3 Endpoint and Regulatory Path for Belapectin Full Approval - Quiver Quantitative
Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension - Yahoo Finance
Galectin Announces FDA Agreement on Phase 3 Endpoint and Q3 2026 Protocol Filing for Belapectin - TradingView
FDA backs Galectin (NASDAQ: GALT) belapectin Phase 3 plan in MASH - Stock Titan
GALT Stock Surges 22%On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial - Mena FN
Galectin Therapeutics Inc (GALT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Galectin Therapeutics Inc (GALT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Galectin Therapeutics Inc (GALT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Galectin Therapeutics Inc (GALT) Institutional Confidence - TradingKey
Galectin Therapeutics Inc (GALT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Galectin Therapeutics Inc (GALT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Galectin Therapeutics Inc (GALT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Galectin Therapeutics Inc (GALT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Galectin Therapeutics Inc (GALT) Valuation: PE, PB & Fair Value Analysis - TradingKey
GALT Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Faces Investor ScrutinyQuarterly Profit Report - newsline.com
GALT Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Advances PipelineDividend Earnings Report - newsline.com
GALT Stock Price, Quote & Chart | GALECTIN THERAPEUTICS INC (NASDAQ:GALT) - ChartMill
Galectin Therapeutics CMO Jamil Khurram sells $1,761 in GALT stock By Investing.com - Investing.com India
Galectin Therapeutics CMO Jamil Khurram sells $1,761 in GALT stock - Investing.com
Galectin Therapeutics (GALT) CMO sells 568 shares after option exercise - Stock Titan
H.C. Wainwright Maintains Galectin Therapeutics(GALT.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Galectin Therapeutics (GALT) Unveils New Insights from NAVIGATE Trial at EASL 2026 - GuruFocus
GALT Q1 2026 Earnings: EPS Misses Estimates as Clinical Development ContinuesPre-Earnings Setup - thelegaladvocate.com
Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis - The Manila Times
Galectin Therapeutics (GALT) Holds Near $2.50 After Modest DeclineATR Stop - Newser
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
GALT Q1 2026 Earnings: Narrowed Loss Amid Clinical Progress, Stock RallyGuidance Accuracy Score - The Legal Advocate
Galectin Therapeutics (GALT) Q1 2026 Results Miss Estimates — EPS $-0.08 vs $-0.06Special Dividend Alert - Newser
Number of shareholders of Galectin Therapeutics Inc. – NASDAQ:GALT - TradingView
TradingKey - TradingKey
Galectin Therapeutics 1Q Research and Development Expenses $2.2M >GALT - Moomoo
Galectin Therapeutics Q1 2026 Financial Report: Earnings, Balance Sheet, and Key Disclosures - Minichart
Galectin Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
0.23%
0.76%
자본화:
|
볼륨(24시간):